Hiring?

Trillium Eye Care Pre-IPO

South East, USA

Short Summary

Join this international health care group expand clinics in North America. Convertible Note pays 10% interest which converts into Stock pre-IPO. Company is targeting an IPO in the US at 5X Return to Investors.

Overview

Target
1'400'000CHF
Minimum
4'900CHF
Investment Raised
99'000CHF
Previous Rounds N/A
Stage Profitable
Investor Role

Highlights

  • A Pre-IPO Healthcare Company with Significant Growth Potential
  • 10% Return on Invested Capital; Convertible into Stock
  • Company is targeting stock listing in the US
  • Diversified operations in US and Canada
  • A stable and recession-proof industry - 94% businesses profitable per stats
Please note: Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence.

Ask a question

Got a question about this project?

Sign up to view the full pitch

It's free to discover the next big thing

Already have an account?

Similar Projects

0% raised

Med Spa looking to expand

location_on South East, USA

Our Med Spa is the home of affordable luxury offering massage, facials, laser hair removal and body contouring services offered thru monthly memberships.

99'000 CHF

Target

990 CHF

Min per Investor

0% raised

Aesthetic/facial Bar

location_on Midwest, USA

Tune Up medical aesthetics and facials provides medical injectables and facial services to its clients. We are geared toward busy, working-class men and women who want to enhance their features and increase their confidence.

290'000 CHF

Target

19'000 CHF

Min per Investor

Featured
30% raised

Cannabinoid Biotechnology

location_on West, USA

Emerald Health Pharmaceuticals; a biotech company entering Phase 2 human studies with patented unique cannabinoid science & technology focused on diseases like multiple sclerosis and Parkinson's disease; 180+ yrs mgt-team experience; $16M raised.

9'900'000 CHF

Target

4'900 CHF

Min per Investor

load one similar proposal